Immupharma (IMM)

 

Latest News

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

ImmuPharma completes sharing agreement with Lanstead

ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...

All News

DateHeadlineSource
30-06-17Result of AGMRNS
30-06-17Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
30-06-17Update on LupuzorT Pivotal Phase III StudyRNS
07-06-17Annual Report & Notice of AGMRNS
01-06-17ImmuPharma losses widenStockMarketWire
01-06-17Final ResultsRNS
22-05-17Notification of Full Year ResultsRNS
17-05-17Lupuzor study on track, says ImmuPharma StockMarketWire
17-05-17Update on Lupuzor Phase III StudyRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
24-03-17ImmuPharma to present at Master Investor ShowRNS
22-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
10-03-17?4.1 Million Fund Raise via Accelerated BookbuildRNS
10-03-17Accelerated Bookbuild for the Issue of EquityRNS
06-03-17Holding(s) in CompanyRNS
17-02-17Holding(s) in CompanyRNS
25-01-17Update on Lupuzor Phase III StudyRNS
24-01-17Change of AdviserRNS
29-12-16Holding(s) in CompanyRNS
22-12-16ImmuPharma completes Lupuzor patient recruitment StockMarketWire
22-12-16Update on Lupuzor Pivotal Phase III StudyRNS
16-11-16ImmuPharma update on cancer compound StockMarketWire
16-11-16Update on Cancer Compound IPP-204106 'Nucant'RNS
09-11-16Holding(s) in CompanyRNS
26-10-16Holding(s) in CompanyRNS
24-10-16ImmuPharma fundraising StockMarketWire
21-10-16Close of Accelerated BookbuildRNS
21-10-16ImmuPharma placing StockMarketWire
21-10-16Proposed Accelerated Bookbuild for Vendor PlacingRNS
30-09-16ImmuPharma losses increase StockMarketWire
30-09-16Half-year ReportRNS
14-09-16ImmuPharma update on Lupuzor study StockMarketWire
14-09-16UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDYRNS
07-09-16ImmuPharma to open new site in Lupuzor study StockMarketWire
07-09-16UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDYRNS
21-07-16Holding(s) in CompanyRNS
20-07-16Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account